默克和辉瑞公司宣布埃格列净(ertugliflozin)伍用西格列汀(sitagliptin)100 mg/d和二甲双胍≥1500 mg/d,治疗2型糖尿病Ⅲ期临床试验达到主终点A1C降低。Ⅲ期临床双盲、随机、安慰剂对照试验入选463名2型糖尿病患者,基线A1C为7.0%~10.5%。按1∶1∶1随机分到埃格列净5和15 mg组及安慰剂组,治疗26周。结 Merck and Pfizer Inc. announced that their phase III clinical trial of type 2 diabetes mellitus achieved a primary endpoint of A1C decline with etanercept in combination with sitagliptin 100 mg / day and metformin ≥ 1500 mg / day. A phase III, double-blind, randomized, placebo-controlled trial enrolled 463 patients with type 2 diabetes. The baseline A1C ranged from 7.0% to 10.5%. The patients were randomly assigned to receive epristeride 5 and 15 mg and placebo at a ratio of 1: 1: 1 for 26 weeks. Knot